PLYMOUTH, MN, UNITED STATES, – ProMed Pharma, a leading contract development and manufacturing organization (CDMO) specializing in long-acting injectable and implantable drug delivery systems, has announced a significant agreement to establish a second dedicated manufacturing suite at its Niagara Lane facility in Plymouth, Minnesota. This suite will be tailored for the handling and manufacture of highly potent active pharmaceutical ingredients (HPAPIs), supporting the development and future commercial production of complex generic drug products.
This latest commitment underscores the increasing market demand for specialized manufacturing capacities that cater to long-acting and sustained-release therapies. The new suite will feature advanced containment technologies and environmental controls, ensuring compliance with current Good Manufacturing Practice (cGMP) requirements while safely processing potent compounds. ProMed aims to leverage its expertise in hot melt extrusion and polymer-based drug delivery systems to meet its partner’s development goals.
James Arps, PhD, Director of Business Development at ProMed Pharma, emphasized that securing this second suite agreement reflects the robust demand for specialized manufacturing solutions in complex pharmaceuticals. The Niagara Lane facility’s flexibility allows it to support a diverse array of product types, including those requiring advanced containment for HPAPIs. As the complex generic market continues to expand, ProMed’s dedicated, customizable manufacturing suites offer pharmaceutical companies a strategic advantage without the burdens of capital investment and operational complexities associated with building proprietary facilities.
With this new suite, ProMed Pharma not only validates its dedicated-suite model but also enhances its capacity to support future pharmaceutical and biotechnology partners seeking dedicated manufacturing space for clinical and commercial production.
Open the full market picture for your next decision →
